153 related articles for article (PubMed ID: 10418920)
1. Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions.
Ekström J; Hu KF; Bengtsson KL; Morein B
Vaccine; 1999 Jun; 17(20-21):2690-701. PubMed ID: 10418920
[TBL] [Abstract][Full Text] [Related]
2. Immunostimulating complexes (ISCOMs) for nasal vaccination.
Hu KF; Lövgren-Bengtsson K; Morein B
Adv Drug Deliv Rev; 2001 Sep; 51(1-3):149-59. PubMed ID: 11516786
[TBL] [Abstract][Full Text] [Related]
3. Functional aspects of iscoms.
Morein F; Bengtsson KL
Immunol Cell Biol; 1998 Aug; 76(4):295-9. PubMed ID: 9723770
[TBL] [Abstract][Full Text] [Related]
4. The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action.
Grdic D; Smith R; Donachie A; Kjerrulf M; Hörnquist E; Mowat A; Lycke N
Eur J Immunol; 1999 Jun; 29(6):1774-84. PubMed ID: 10382739
[TBL] [Abstract][Full Text] [Related]
5. Enhanced soluble production of cholera toxin B subunit in Escherichia coli by co-expression of SKP chaperones.
Zhang Y; Qiao X; Yu X; Chen J; Hou L; Bi Z; Zheng Q; Hou J
Protein Expr Purif; 2017 Oct; 138():1-6. PubMed ID: 28673733
[TBL] [Abstract][Full Text] [Related]
6. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
[TBL] [Abstract][Full Text] [Related]
7. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
8. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
[TBL] [Abstract][Full Text] [Related]
9. The identification of plant lectins with mucosal adjuvant activity.
Lavelle EC; Grant G; Pusztai A; Pfüller U; O'Hagan DT
Immunology; 2001 Jan; 102(1):77-86. PubMed ID: 11168640
[TBL] [Abstract][Full Text] [Related]
10. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
Lycke N
Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses.
Sjölander S; Drane D; Davis R; Beezum L; Pearse M; Cox J
Vaccine; 2001 Jul; 19(28-29):4072-80. PubMed ID: 11427284
[TBL] [Abstract][Full Text] [Related]
12. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
13. A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with Echinococcus granulosus surface antigens iscoms.
Carol H; Nieto A
Vet Immunol Immunopathol; 1998 Sep; 65(1):29-41. PubMed ID: 9802574
[TBL] [Abstract][Full Text] [Related]
14. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.
Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K
Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937
[TBL] [Abstract][Full Text] [Related]
15. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
[TBL] [Abstract][Full Text] [Related]
16. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
[TBL] [Abstract][Full Text] [Related]
17. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant.
Campos EA; Namikoshi J; Maeba S; Yamamoto M; Fukumoto M; Yamamoto H
J Oral Sci; 2003 Mar; 45(1):25-31. PubMed ID: 12816361
[TBL] [Abstract][Full Text] [Related]
18. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.
Maeyama J; Isaka M; Yasuda Y; Matano K; Kozuka S; Taniguchi T; Ohkuma K; Tochikubo K; Goto N
Microbiol Immunol; 2001; 45(2):111-7. PubMed ID: 11293476
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
20. Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses.
Kato H; Fujihashi K; Kato R; Yuki Y; McGhee JR
J Immunol; 2001 Mar; 166(5):3114-21. PubMed ID: 11207263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
